Immunotherapy with dendritic cells for prostate cancer

Dendritic cell vaccination

Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge)

Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study

[State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus]

[Active immunotherapy of prostate cancer with a focus on dendritic cells]

TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate cancer

[Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy]

Immunology and immunotherapy approaches for prostate cancer

Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells–a pilot study